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Single-tube, dual channel 
pentaplexing for the identification 
of Candida strains associated with 
human infection
Mohd Hanif Jainlabdin1,2, Ambalika Batra  1, edith Sánchez paredes3,  
francisca Hernández Hernández3, Guoliang fu4 & Jorge tovar-torres1
invasive candidiasis is one of the most common nosocomial fungal infections worldwide. Delayed 
implementation of effective antifungal treatment caused by inefficient Candida diagnosis contributes 
to its notoriously high mortality rates. the availability of better Candida diagnostic tools would 
positively impact patient outcomes. Here, we report on the development of a single-tube, dual channel 
pentaplex molecular diagnostic assay based on Multiplex Probe Amplification (MPA) technology. It 
allows simultaneous identification of C. auris, C. glabrata and C. krusei, at species-level as well as of six 
additional albicans and non-albicans pathogenic Candida at genus level. the assay overcomes the one-
channel one-biomarker limitation of qPCR-based assays. Assay specificities are conferred by unique 
biomarker probe pairs with characteristic melting temperatures; post-amplification melting curve 
analysis allows simple identification of the infectious agent. Alerting for the presence of C. auris, the 
well-characterised multi-drug resistant outbreak strain, will facilitate informed therapy decisions and 
aid antifungal stewardship. the MpA-Candida assay can also be coupled to a pan-fungal assay when 
differentiation between fungal and bacterial infections might be desirable. Its multiplexing capacity, 
detection range, specificity and sensitivity suggest the potential use of this novel MPA-Candida assay in 
clinical diagnosis and in the control and management of hospital outbreaks.
Invasive fungal infections (IFIs) are a significant threat to immunocompromised patients1. The immune system 
of healthy individuals may also be compromised by severe health conditions such as burns, diabetes mellitus, 
organ transplantation, human immunodeficiency virus infections and disorders such as leukaemia and other 
malignancies. Invasive and aggressive medical practices and treatments such as surgery, the use of catheters, 
radiation and chemotherapy put patients at high risk from invasive fungal infections2. It is estimated that invasive 
fungal infections claim the lives of around 1.5 million people every year but epidemiological data are often nega-
tively affected by challenges associated with laboratory diagnoses such as inefficient methodology and inadequate 
regional logistics3.
Among the prevalent fungal pathogens, species of the yeast Candida are a leading causes of invasive fun-
gal disease and are commonly associated with nosocomial infections4. Candida species contribute 10–20% of 
hospital-associated infections5 and are responsible for 5–15% of bloodstream infections among immunocom-
promised and extreme age patients6. More than 90% of invasive candidiasis cases are caused by C. albicans, C. 
glabrata, C. parapsilosis, C. tropicalis and C. krusei7,8. In the United Kingdom, the most recent estimate of invasive 
candidiasis was 5,142 cases in 2013, with population incidence of 3.1 per 100,000 and 10.1 per 100,000 for candi-
demia and invasive candidiasis respectively9. Improving the diagnosis and management of candidiasis is essential 
for the timely prescription of correct therapeutic drugs to patients and the acquisition of reliable epidemiological 
data3,10. It is also important for the management and control of nosocomial outbreaks11.
Accurate identification of pathogenic Candida to species-level is key for effective treatment, as not all species 
are equally susceptible to individual antifungal drugs12. This is evidenced by intrinsic resistance of C. krusei to 
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fluconazole and lower susceptibility of C. glabrata towards most antifungal drugs, including amphotericin B13,14. 
Along with species-level identification, the ability to detect other medically important species has become crucial 
as the emergence of non-albicans Candida species continues to rise. In recent years, multi-drug resistant C. auris 
outbreaks have been reported across major hospitals in the UK15,16. Public Health England Mycology Reference 
Laboratory has reported that all C. auris isolates in the UK are resistant to fluconazole, with variable resistance 
to polyenes (~20% for amphotericin B) and echinocandins (~10%)17. First reported in Japan as the cause of 
an ear infection18 C. auris has been shown to have a close genetic relationship with C. haemulonii. It is crucial 
therefore to differentiate between these two species for the efficient management and control of nosocomial C. 
auris outbreaks, as under such circumstances the isolation of carriers and the release of non-carriers is a clinical 
priority16,19.
Recent advances in the development of new and reliable methods of fungal nucleic acid detection hold prom-
ise for the early identification of fungal pathogens20,21. Conventional microbiological techniques such as blood 
cultures are positive in only 38–50% of proven invasive candidiasis9,22, while immunological detection of fungal 
cell wall markers suffer from low specificity and sensitivity23. Real-time PCR-based molecular methods such as 
Genesig kit (PrimerDesign), ViPrimePLUS Candida albicans qPCR kit (Vivantis) and Luminex xTAG Fungal 
Assay (Luminex Molecular Diagnostics) appear promising. However, these and similar products are often limited 
in the number of species that can be identified in a single assay and suffer from low multiplexing capacity.
Multiplex Probe Amplification (MPA) was developed as an alternative biomarker amplification method that 
overcomes such limitations24. It allows detection of multiple analytes in a single fluorescence detection channel; 
up to six probes with a unique melting temperature can be labelled with the same fluorophore and detected. Here 
we report on the development of MPA technology for identification of the main Candida strains that cause inva-
sive candidiasis. As a pre-clinical, proof of concept study, an MPA-Candida assay was engineered to incorporate a 
pan-Candida biomarker probe able to identify at genus level the nine Candida species most frequently associated 
with candidiasis (C. albicans, C. dubliniensis, C. tropicalis, C. parapsilosis, C. guilliermondii, C. haemulonii, C. 
krusei, C. glabrata and C. auris). In addition, three species-specific biomarker probes were incorporated for the 
individual identification of multidrug-resistant C. auris, C. glabrata and C. krusei. The in-vitro characterisation of 
the MPA-Candida assay reported here highlights the potential of this novel molecular tool in clinical diagnosis 
of candidiasis, disease management, and in the control of nosocomial outbreaks. Informed prescription of the 
most suitable chemotherapy at the first time of asking will not only benefit patients but could also contribute to 
antifungal stewardship efforts worldwide.
Results
Identification and characterisation of fungal DNA biomarkers. The basic principles of MPA tech-
nology are described and illustrated in the Methods section. Short biomarker nucleotide sequences that could 
reliably differentiate fungi from bacteria (pan-fungal), Candida from any other fungi (pan-Candida) and discern 
C. auris, C. glabrata and C. krusei from each other and from all other Candida species were identified within 
the rDNA locus25–27, as described in the Methods section. The pan-fungal probe lies within the internal tran-
scribed spacer 2 (ITS2) region (Fig. 1). Reverse BLASTing of this sequence amongst the fungi demonstrated 100% 
sequence similarity with 100% query cover for all top 100 hits (Table S1). Optimised universal primers ITS3 and 
LR1 were used to generate an amplicon containing the pan-fungal biomarker. Amplicon sizes in the range of 279 
bp (Candida auris) and 451 bp (Lichtheimia corymbifera, formerly Absidia corymbifera) were obtained.
Genus-specific (pan-Candida) and species-specific Candida biomarkers lie within the D1/D2 region of the 
LSU rDNA gene locus (Fig. 1). C. krusei, C. glabrata and C. auris-specific probes had 100% sequence similar-
ity with 100% query cover to their respective Candida species (Table S1). The pan-Candida probe had 100% 
sequence similarity with all Candida species tested. Similarity to five other fungi rarely associated with human 
infection was also observed with this probe (Table S1). All selected biomarker sequences showed no intraspecies 
strain-to-strain variability in multiple alignments (Tables S2 and S3). A forward primer pair to amplify Candida 
species was optimised from universal primer LR0, while the reverse primer GSCand-R, was designed specifically 
for the assay (Table S4). The primer set generated a 381 bp biomarker-containing amplicon for most Candida 
species. C. krusei, C. auris and C. guilliermondii amplicons were 370 bp in size. Nucleotide sequences for all 
MPA-Candida probes and amplification primers are shown in Table S4.
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Figure 1. Relative position of amplification primers and probes along the fungal ribosomal genes. The relative 
location of two amplicons and five fungal biomarker target sequences are displayed. Pan-fungal primer set ITS3 
and LR1 and pan-Candida primer set LR0 and GSCand are depicted as arrows. FAM-labelled pan-fungal, C. 
krusei-specific, C. glabrata-specific and pan-Candida probes are marked with a green circle; the HEX-labelled C. 
auris-specific probe is marked with an orange circle. Quencher molecules are shown as black circles. Not drawn 
to scale.
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Design of Candida-specific MPA probes and melting curve analysis. MPA probes consist of two 
partly complementary oligonucleotides, the dual-labelled target-hybridising oligonucleotide (THO) and a cor-
responding partially complementary oligonucleotide (PCO). Each THO is fully complementary to one of the 
Candida-specific biomarker target sequences identified above. The pan-Candida, and C. krusei, C. glabrata and 
C. auris species-specific probes hybridise with high affinity to their respective targets within the hypervariable 
D1/D2 LSU rDNA region. The PCO sequences were engineered to have several nucleotide mismatches against 
their corresponding THO sequence (Table S4). All Candida biomarker target sequences are located close to each 
other within the LSU region and are amplified by a single set of primers (Fig. 1). Initial characterisation of all five 
MPA probes (THOs plus their corresponding PCO sequences) using UNAFold software allowed confirmation of 
their theoretical melting profiles (Fig. 2). A melting curve overlap between the C. krusei-specific probe and the 
internal control probe as well as between the C. auris and the C. glabrata-specific probes is apparent. However, 
their independent analysis is not affected under experimental conditions as each overlapping probe is labelled 
with a different fluorophore. The pan-Candida, C. krusei-specific and C. glabrata-specific probes were labelled 
with 6-carboxyfluorescein (FAM) whereas the C. auris-specific and the internal control probes were labelled with 
Hexachloro-fluorescein (HEX).
Experimental assembly of all MPA-Candida probes in a single reaction tube consistently generated five spe-
cific melt peaks collected in two fluorescence detection channels. C. krusei, C. glabrata and pan-Candida probes 
were detected in the FAM channel, whereas the C. auris and internal control probes were detected in the HEX 
channel (Fig. 3, panels a and b respectively). Each peak represents the maximum rate of dissociation between 
THO and PCO at a given temperature during melting curve analysis. These melt curves provide an important 
no-template control to compare against the melt curves obtained when target DNA is present and amplified in 
the reaction.
Design of a complementary pan-fungal qpcR assay. To complement the functionality of the 
MPA-Candida assay we designed a qPCR pan-Fungal assay that may be used alongside for enhanced fungal 
detection range. It operates under the same DNA amplification conditions and, when used, allows detection of a 
wider range of clinically relevant fungal pathogens. Fluorescence emission following qPCR biomarker amplifica-
tion is monitored at 465 nm in the FAM channel. This reaction tube also contains a HEX-labelled internal control 
probe. Nucleotide sequences for the corresponding amplification primers and the pan-fungal probe are shown 
in Table S4.
Analytical specificity of the combined MPA-Candida and pan-fungal assays. The specificity of 
the MPA-Candida assay was tested independently using recombinant plasmids harbouring C. albicans, C. dub-
liniensis, C. krusei, C. glabrata, C. auris, C. parapsilosis, C. tropicalis, C. haemulonii, C. guilliermondii target bio-
markers. Following DNA amplification their corresponding melt curves were analysed. All nine Candida species 
showed reduction/ablation of their melt peaks at 40 °C, corresponding to the pan-Candida probe, when com-
pared to their corresponding no-template controls (Fig. 4). This demonstrates the assay’s capability to identify 
at genus level the nine Candida species most commonly associated with human infection. In addition, specific 
identification of three important drug-resistant Candida species, namely C. krusei, C. glabrata and C. auris, was 
demonstrated by additional melt peak reductions at 30 °C and 46 °C in the FAM channel and at 48 °C in the HEX 
channel respectively (Fig. 4, panels b–d). None of the other Candida species tested showed a melt curve decrease 
at those temperatures thus demonstrating the species-specificity of the assay for C. auris, C. glabrata and C. krusei.
Assay specificity was also tested using genomic DNA (Table 1). None of the heterologous DNAs tested were 
detected in the MPA-Candida assay; the internal control present in every sample demonstrated assay functional-
ity and ruled out the possibility of false negative results. The pan-Fungal assay identified all nine Candida species 
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Figure 2. Theoretical Tm prediction for the MPA probes used in this study. Predicted melting curves for 
THO:PCO hybrids specific for C. krusei, C. glabrata, pan-Candida, C. auris and Internal Control (IC) probes 
using UNAFold software (http://unafold.rna.albany.edu/) are shown. Heat capacity (Cp) is the maximum 
amount of heat needed to change the temperature of one mole of a hybrid by one degree at constant pressure, 
which defines the melting temperature (Tm).
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tested as well as a range of pathogenic filamentous fungi, including Aspergillus fumigatus, Fusarium solani, 
Penicillium rubens and Mucor circinelloides. Genomic DNA from bacteria that form part of the normal human 
flora, including Staphylococcus epidermidis, Staphylococcus aureus, Proteus mirabilis and Escherichia coli, was not 
detected under the conditions used. All bacterial and fungal genomic DNAs were tested at 105 genome equiva-
lents (GEs) per reaction (Table 1; Fig. S1). DNA amplification of the internal control was consistently detected in 
the HEX detection channel. Early amplification (C = 16) of the same E. coli genomic DNA samples was observed 
using the universal bacterial 16S primer set.
Assay sensitivity and limits of detection. The limits of detection of the MPA-Candida assay were deter-
mined using a range of 100–105 GEs. DNA amplification profiles and the magnitude of melting curve reductions 
observed were evaluated against their corresponding no-DNA controls (NDC; Fig. 5). The amplification cycle 
threshold was set at 45 cycles to avoid inconclusive late amplification. Crucially, in this assay, interpretation of 
the specificity of amplification relies totally on the melt curve analysis derived from the data collected in just two 
detection channels, FAM and HEX.
Measurable reductions in the pan-Candida peaks compared to no DNA controls allowed genus-level iden-
tification of all samples, down to 10 GEs for C. krusei and C. auris and 100 GEs for C. albicans, C. dublinien-
sis, C. glabrata, C. parapsilosis, C. tropicalis, C. haemulonii and C. guilliermondii (Fig. 5 and Table 2). The C. 
glabrata-specific probe (46 °C peak in FAM channel) detected down to 100 C. glabrata GEs while the C. krusei- 
and C. auris-specific probes (30 °C peak in FAM channel and 48 °C peak in HEX channel) detected down to 10 
GEs, a 10-fold higher sensitivity compared to the C. glabrata probe (Fig. 5, panels a to d).
The limits of detection of the pan-Fungal assay were determined from amplification curves monitored in 
the FAM channel. In general, Candida species can be routinely detected down to 10 GEs except for C. glabrata, C. 
tropicalis and C. guilliermondii which required a minimum of 100 GEs in the reaction. The limits of detection for 
both the MPA-Candida and pan-Fungal assays are summarised in Tables 2 and 3 respectively.
Amplification efficiency and reproducibility of the pan-Fungal assay. Amplification efficiency of 
the pan-Fungal quantitative assay was calculated from the slopes generated in independent experiments using 
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Figure 3. A two-channel MPA detection system with internal control and Candida-specific melt curve profiles. 
(a) The fluorescence negative derivative (−dF/dT) melt peaks obtained from dissociation between THO and 
PCO for the C. krusei-specific, pan-Candida and C. glabrata-specific probes in the FAM channel; (b) Melt 
peaks for the internal control (IC) and C. auris-specific MPA probes in the HEX channel. Their specific melting 
temperatures are indicated.
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Figure 4. Melt curve analysis specificity of the MPA-Candida assay. FAM and HEX channel post-amplification 
melt curve profiles of nine different Candida species (dotted lines) compared to their corresponding no-
template controls (solid lines). (a) Genus-level identification of the indicated Candida species is demonstrated 
by ablation of the pan-Candida peak in the FAM channel; decrease of the internal control (IC) peak in the 
HEX channel confirms assay functionality. (b,c) Species-specific identification of C. krusei and C. glabrata 
respectively, as demonstrated by a significant reduction in their corresponding melt peaks in the FAM channel; 
note that in both cases the pan-Candida peak is also ablated. (d) Species-specific identification of C. auris, as 
demonstrated by a significant reduction in its melt peak in the HEX channel and ablation of the pan-Candida 
peak in the FAM channel. In all cases diagnosis is supported by the corresponding DNA amplification curves 
and associated Ct values (Table S5).
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target biomarkers from eight Candida species. Standard curves were derived for each species in three independ-
ent experiments, each with triplicate samples incorporating a total of 360 data points. The efficiency range was 
82.99 to 104.49% (Table S6), and the slopes between the standards were not significantly different (ANCOVA, 
p = 0.8561). A representative standard curve with an overall efficiency of 92.56% and correlation coefficient, 
R2 = 0.9992 is shown in Fig. 6.
Assay reproducibility was assessed using target biomarker dilutions spanning five orders of magnitude, from 
106 to 102 plasmid DNA copies per reaction. The pan-Fungal assay reproducibly identified all Candida spe-
cies over the range of dilutions tested, with intra- and inter-assay CV values lower than 5% (Tables S7 and S8 
respectively).
comparison of assay performance. Given the importance of multi-drug resistant C. auris for clinical and 
epidemiological studies, we compared the performance of the MPA-Candida assay against a commercially avail-
able single-purpose C. auris identification kit (Genesig, PrimerDesign). As can be seen in Fig. 7, comparable C. 
auris identification efficiency was observed under the same experimental conditions, with correlation coefficient 
R2 = 0.997, PCR efficiency (E) = 79.02% for the Genesig kit and R2 = 0.997, E = 125.09% for the MPA-Candida 
assay C. auris species-specific identification and R2 = 0.993, E = 73.57% for the Candida genus-specific identifica-
tion respectively. In contrast to the Genesig kit, the MPA-Candida assay showed no cross-reactivity with genomic 
DNA from C. haemulonii, a close relative of C. auris (data not shown).
Discussion
In this study, biomarkers for the detection of all fungal species (pan-fungal), all Candida species (pan-Candida) 
and the species-specific identification of C. krusei, C. glabrata and C. auris were incorporated into a novel molec-
ular diagnostic assay based on MPA technology. C. auris, C. glabrata and C. krusei were selected for species-level 
identification due to their well-known antifungal drug resistant phenotypes. In this version of the assay, detection 
range was widen by incorporating genus-level detection of six additional Candida species capable of causing 
human invasive candidiasis, namely C. albicans, C. dubliniensis, C. tropicalis, C. guilliermondii, C. parapsilosis and 
C. haemulonii. The MPA-Candida assay contains probe pairs from the variable D1/D2 domains of the LSU rDNA 
locus. The initial 381-nucleotide sequence from the 5′ end of the LSU region has been shown to contain great 
intra-genus sequence diversity for Candida species and has been used previously to distinguish at species-level 
all clinically relevant Candida species28,29. BLAST analysis of the pan-Candida probe sequence found no iden-
tity to any prokaryotic or eukaryotic gene sequences, with the exception of five environmental yeasts, namely 
Yamadazyma olivae, Kregervanrija pseudodelftensis, Zygosaccharomyces rouxii, Spathaspora sp and Saccharomyces 
Species
MPA-Candida assay Pan-Fungal assay
Melting curve analysis Ct value Ct value
FAM HEX
FAM HEX
FAM HEX
CK PC CG IC CA PF IC
Candida
C. albicans − + − + − 23.40 26.00 22.00 21.00
C. krusei + + − + − 22.20 26.20 22.90 25.60
C. glabrata − + + + − 24.40 26.50 24.30 24.80
C. auris − + − + + 23.60 29.00 23.00 26.20
C. haemulonii − + − + − 24.60 27.80 21.00 26.00
C. dubliniensis − + − + − 23.60 28.00 22.00 26.30
C. parapsilosis − + − + − 23.90 26.90 21.80 25.40
C. tropicalis − + − + − 23.50 26.00 21.00 26.00
C. guilliermondii − + − + − 23.60 26.50 22.90 26.50
Moulds*
A. fumigatus − − − + − − 28.10 22.90 23.40
F. solani − − − + − − 28.50 21.10 23.20
P. rubens − − − + − − 27.10 16.60 20.10
M. circinelloides − − − + − − 28.00 17.00 24.10
Bacteria*
S. aureus − − − + − − 29.70 − 22.80
S. epidermidis − − − + − − 28.90 − 23.50
P. mirabilis − − − + − − 28.40 − 23.00
E. coli − − − + − − 28.00 − 23.20
Table 1. Specificity of the MPA-Candida and pan-Fungal assays. *Fungal and bacterial genomic DNAs were 
tested at 105 genome equivalent per reaction. Ct: Threshold Cycle, the cycle intersection at the point where the 
curve first clearly rises off baseline value; FAM: Detection channel (465 nm/510 nm); HEX: Detection channel 
(533 nm/580 nm); CK: C. krusei-specific peak (30 °C); PC: Pan-Candida peak (40 °C); CG: C. glabrata-specific 
peak (46 °C); CA: C. auris-specific peak (48 °C); IC: Internal Control-specific peak (34 °C); PF: pan-fungal; +: 
Change in melt curve detected; −: No change detected.
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Figure 5. Amplification profiles and melt curve analyses of genomic DNA in MPA-Candida assays. 
Amplification reactions containing a range of 1 to 105 GEs per reaction were set up. Post-amplification melt 
curve analysis was then carried out. Amplification plots of C. albicans (a), C. krusei (b) and C. glabrata (c) 
and their corresponding melt curve profiles are shown demonstrating changes in the pan-Candida peaks 
proportional to the number of GEs present in the reaction. Similar results can be seen for C. krusei and C. 
glabrata at their corresponding species-specific peaks in the FAM channel. (d) Amplification plots of C. auris 
and their corresponding melt curve profiles showing proportional changes to their pan-Candida (i) and C. 
auris-specific (ii) peaks in the FAM and HEX channels respectively. The horizontal dotted line is fixed as the 
threshold value of fluorescence.
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cerevisiae, the latter phylogenetically related to Candida30,31. Cross-detection of S. cerevisiae by the pan-Candida 
probe is not of medical concern as invasive infections caused by S. cerevisiae are rare compared to those caused by 
Candida and standard antifungal therapy with fluconazole is efficient in controlling such infections32,33.
The pan-fungal probe used in this study was selected from the ITS2 region, which was amplified using the uni-
versal primer set ITS3 and LR127. Although there is no single locus for global fungal identification, the whole ITS 
region (ITS1-5.8-ITS2) is generally accepted as a universal fungal DNA barcode26. To ensure assay functionality 
and avoid false negative results, a unique internal control probe sequence was designed and incorporated into 
both MPA-Candida and pan-Fungal assays. Monitoring the presence of the internal control plasmid sequence 
was independent of the presence or absence of fungal target sequences in the assay.
Species
Detection 
channel(s)
Limit of 
detection (GEs)
Ct <45  
cut-off value
C. auris FAM, HEX 10 43.60, 32.40
C. krusei FAM 10 41.00
C. glabrata FAM 100 41.30
C. albicans FAM 100 37.10
C. dubliniensis FAM 100 35.60
C. parapsilosis FAM 100 36.50
C. tropicalis FAM 100 37.90
C. guilliermondii FAM 100 36.50
C. haemulonii FAM 100 37.00
Table 2. Limits of detection of the MPA-Candida assay.
Species
Limit of detection 
(GEs)
Ct <45 cut-off 
value in FAM
Aspergillus flavus 10 40.00
C. auris 10 42.00
C. krusei 10 41.00
C. albicans 10 40.00
C. dubliniensis 10 41.30
C. parapsilosis 10 41.50
C. haemulonii 10 40.00
C. glabrata 100 43.10
C. tropicalis 100 35.00
C. guilliermondii 100 37.30
Table 3. Limits of detection of the pan-Fungal assay.
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Figure 6. Pan-Fungal assay standard curve. Standard curve generated by plotting the mean Ct values as a 
function of target DNA concentration. Ten-fold serial dilutions (106 to 102 GEs) of Candida DNA were analysed 
in three independent experiments, each with three replicates per sample. Error bars represent standard 
deviations (SD) of Ct values. Confidence intervals (CI) of Ct mean values are indicated by the dashed lines.
9Scientific RepoRtS |         (2019) 9:14692  | https://doi.org/10.1038/s41598-019-51198-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
In vitro testing of the MPA-Candida assay demonstrated its capacity for genus-level identification of nine 
medically important Candida species using a pan-Candida probe i.e., C. albicans, C. dubliniensis, C. parapsi-
losis, C. tropicalis, C. guilliermondii, C. haemulonii, C. krusei, C. glabrata and C. auris. Drug-resistant species 
C. krusei, C. glabrata and C. auris can also be simultaneously identified at species level by their corresponding 
species-specific probes. This should allow informed decisions to be made regarding chemotherapy. For example, 
an infection caused by C. albicans would give a positive diagnosis through reduction of the pan-Candida melting 
peak (Figs 4a and 5a). The concomitant absence of any significant change in the species-specific melting peaks for 
C. auris, C. glabrata or C. krusei would suggest the use of first-line antifungals such as fluconazol or itraconazole, 
instead of alternative and more costly second line antifungals recommended for C. auris or C. glabrata infections 
(e.g., micafungin, caspofungin, amphotericin B). In addition, kingdom-level identification by the pan-Fungal 
assay should strengthen clinical decisions where the prokaryotic or eukaryotic nature of the infectious agent is 
uncertain.
Intra-specific variation within the fungal rDNA locus has been shown to be minimal34,35. This includes the ITS 
region and the 26S D1/D2 region (target site for the pan-Candida and species-specific probes). Irinyi et al (2015) 
conducted extensive nucleotide diversity (π) and polymorphic site proportion analysis using 176 fungal species 
with a minimum of two clinical isolates per species. Kurtzman & Robnett (1997) reported intra-specific variation 
within the ~380 bp Candida D1/D2 region to be in the range of 0 to 2 nucleotides. Analysis of the intra-specific 
variability within the nucleotide sequences targeted by the MPA-Candida diagnostic probes using nucleotide 
sequences from reference and multiple clinical isolates/strains for each of the Candida species used in this study 
found no evidence of intra-species variability in their target regions (Tables S2 and S3). For C. auris, we included 
representative sequences from the most important geographical clades (East Asia, South Asia, Africa and South 
America). Taken together, these findings suggest that most if not all natural clinical isolates/strains of a particular 
Candida species should be readily identified by the MPA-Candida assay described in this study.
Inter-species variability within the D1/D2 region of the large ribosomal subunit is, on the other hand, exqui-
site. It has been extensively employed in fungal taxonomical classification and in the molecular identification of 
mould and yeast species, including Candida28,35. Table 1 shows that genomic DNA from a range of moulds and 
bacteria frequently associated with human colonisation/infection is not detected by the MPA-Candida assay; nei-
ther is genomic DNA of human origin. Extensive sequence homology searches using non-redundant nucleotide 
sequence databases that include bacterial, human, mould and yeast DNA sequences found no identical target 
sequences other than those reported on Table S1. Taken together, these data strongly suggest that the possibility of 
false positive diagnostic results due to inter-species cross-reactivity is very low. It is acknowledged however that, 
as for every other molecular diagnostic test, ruling out the possibility of unintended assay cross-reactivity would 
require more extensive sampling across the taxonomic range.
The fact that five different MPA probes are labelled with either of two different fluorophores and analysed 
using two fluorescence detection channels provides a crucial advantage over other real-time qPCR diagnos-
tic tests which use standard hydrolysis probes and are limited to one detection channel per biomarker24. The 
pan-Candida, C. krusei-specific and C. glabrata-specific probes were labelled with FAM; the C. auris-specific and 
internal control probes were labelled with HEX. Although MPA allows labelling of up to six different probes with 
the same fluorophore we sought to avoid analytical ambiguity by using two rather than a single detection channel. 
The C. auris-specific probe has a melting temperature almost identical to that of the C. glabrata-specific probe and 
would overlap significantly in a single channel; the internal control probe has a melting temperature that is less 
than 5 ºC different to the C. krusei-specific probe. Ideally, the melting temperature between the probes labelled 
with the same fluorophore should differ by 5–7 °C. During assay optimisation assembly of the pan-Candida and 
C. glabrata-specific probes labelled with FAM at equivalent concentrations led to a masking of the C. glabrata sig-
nal; reducing the pan-Candida probe concentration to 0.2 µM resolved this issue. The reason for this observation 
is unclear but probe interference in MPA assays has been noted before24.
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Figure 7. Detection of C. auris genomic DNA in MPA-Candida and simplex C. auris qPCR diagnostic kit 
(Genesig). C. auris genomic DNA was detected over five tenfold dilutions ranging from 105–101 GEs per 
reaction. Standard deviations are small and error bars can only be seen in the highest dilution Ct values.
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A separate pan-Fungal assay could assist clinicians in ruling out non-fungal infections before proceeding with 
the diagnosis for candidiasis. A pan-Fungal assay complementary to the MPA-Candida assay was engineered 
using a pan-fungal probe that targets the whole ITS2 region. The ITS2 region has been widely used in fungal 
phylogenetic studies and in detecting fungal pathogens in a range of PCR platforms36,37. Detection channels 
and the reaction protocol for the pan-Fungal assay are consistent with those used in the MPA-Candida assay, 
which enables simultaneous running of both reactions and result analysis in a single run. As the pan-Fungal 
assay is not based on MPA technology only an amplification curve is needed to monitor target amplification. The 
pan-Fungal assay is more straightforward to analyse and could save the precious DNA material and cut the cost 
for unnecessary diagnosis processes. However, combining the current MPA-Candida and pan-Fungal assays into 
a single-tube, single-detection channel reaction might be feasible.
The MPA-Candida assay offers post-amplification melt peak analysis for identification of drug sensitive and 
drug resistant Candida species. In the presence of each target, the corresponding melting peak is either reduced 
in magnitude or ablated when compared with the no-template control. All nine Candida species were detected by 
the pan-Candida probe and each drug resistant species (C. auris, C. glabrata and C. krusei) was simultaneously 
identified by their corresponding species-specific probe. A slight reduction of the C. krusei melting peak was 
noted in the presence of non-krusei Candida DNA throughout this study. This phenomenon has been described 
as “shrunk neighbouring peaks” by Fu et al.24 and does not affect the diagnostic specificity and accuracy of the 
assay. In the presence of C. krusei DNA its corresponding melting peak is clearly reduced or ablated compared 
to a small reduction as in the presence of non-krusei Candida DNA. Overall, assay design and melting peak 
distribution along two detection channels allows easy identification of one or more Candida-specific targets in a 
single-tube format.
Both the MPA-Candida and pan-Fungal assays were shown to detect down to 100 target GEs and could con-
fidently detect 10 C. krusei and C. auris GEs. This range of detection is equivalent to the clinical range of candi-
demia of 5 to 100 CFU/ml38 and compares well with other commercially available kits. For example, SeptiFast 
(Roche) could detect fungal DNA in a range of 30 to 100 CFU/ml blood39, and MycoReal Candida kit (Ingenetix) 
could detect from 5 to 10 CFU/ml blood40. In the MPA-Candida assay, amplification of DNA from any of the 
Candida species is detected in the FAM channel whereas amplification of C. auris DNA or the internal control 
DNA is detected in the HEX channel. Post-amplification melt curve analysis is essential for the qualitative identi-
fication of drug-sensitive or drug-resistant species in the MPA-Candida assay. Interestingly, although DNA ampli-
fication from a single copy of C. krusei genomic DNA could be detected (Ct = 42.52 ± 2.07) its corresponding 
melting peak was not reduced significantly compared to the no-DNA control peak. Result interpretation therefore 
must always be guided by the melt curve analysis, especially at very low infection loads. Sensitivity testing using 
plasmid-cloned target DNAs demonstrated that the MPA-Candida assay can reliably detect down to 100 copies 
of target DNA per reaction (Tables S7 and S8). Given that each fungal cell contains around 50 rDNA copies, 100 
copies of target DNA is equivalent to a limit of detection of 2 GEs/2 CFUs. The data suggests that the molecular 
environment within the reaction tube is important in determining assay sensitivity.
The MPA-Candida assay was evaluated for its capacity to identify the presence of the multi-drug resistant, out-
break strain C. auris. Assay sensitivity was found to be up to 10 GEs per reaction at both genus- and species-level. 
Its limit of detection is comparable to that of the Genesig kit (PrimerDesign), a simplex C. auris identification kit, 
when tested over a five order of magnitude C. auris DNA dilution range (Fig. 7). Importantly, no cross-reactivity 
was observed with C. haemulonii, a closely related species that is frequently misidentified as C. auris by com-
mercial biochemical-based yeast identification systems such as Vitek 2 (BioMérieux) and BD Phoenix (BD 
Diagnostics)41.
In summary, the MPA-Candida assay allows detection of five different targets in just two detection channels. 
The multi-drug resistant C. krusei, C. glabrata and C. auris strains can be efficiently discriminated from other 
Candida species by a straightforward melt curve analysis. These features would allow clinical decision making to 
be expedited so that the most efficient chemotherapy can be prescribed in a timely fashion, thus improving patient 
outcomes. The MPA-Candida assay is suitable for adaptation to other qPCR platforms (Qiagen’s Rotor-Gene Q 
2-Plex HRM, Applied Biosystems 7500), which could allow integration into laboratories that operate under con-
ditions of limited resources.
Methods
Multiplex probe amplification (MPA) probes and melting curve analysis. Each probe for every 
target is composed of two oligonucleotides; a dual-labelled target-hybridising oligonucleotide (THO) and 
a partially-complementary oligonucleotide (PCO) (Fig. 8a). The THO binds to its intended biomarker target 
sequence with high affinity; it also binds to its corresponding PCO, albeit with lower affinity. The PCO incorpo-
rates mismatched nucleotides and has slightly lower annealing temperature compared to that of the THO and 
its fully complementary target sequence. In the absence of target DNA, the THO will bind to its corresponding 
PCO and will display a characteristic dissociation peak in the melt curve analysis. In the presence of DNA target 
sequence, the THO will preferentially anneal to its target and will be hydrolysed during the extension steps of 
PCR. Consequently, the post-amplification melting curve analysis will show a decreased melting peak compared 
to the no-target control as little or no THO:PCO hybrid can be formed. The THO:PCO hybrid probe shows max-
imum fluorescence at a low temperature which decreases as the probe dissociates with increasing temperatures 
(Fig. 8b). The highest rate of fluorescence change is observed in the melting curve analysis when 50% of the THO 
has dissociated from the PCO at the specific melting temperature (Fig. 8c)24.
fungal strains and bacterial isolates. Candida strains (C. albicans, C. glabrata, C. tropicalis, C. dub-
liniensis, C. krusei, C. guilliermondii and C. parapsilosis) were a kind gift of Professor Julian Naglik (King’s 
College London). C. auris (NCPF 8971) and C. haemulonii (NCPF 8402) strains were purchased from Public 
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Health England, Bristol, UK. Mould and bacterial strains A. fumigatus, F. solani, M. circinelloides, P. rubens, 
S. aureus, S. epidermidis, E. coli, and P. mirabilis were obtained from the Molecular Microbiology laboratory, 
Centre for Biomedical Sciences, Royal Holloway University of London. Fungal isolates were sub-cultured onto 
Sabouraud-Dextrose Agar (SDA; Sigma-Aldrich) and incubated at 37° and 25 °C for yeast and mould respec-
tively for 15–24 hours. For liquid cultures, single yeast colonies were inoculated in yeast-extract peptone dextrose 
(YPD) broth (Sigma-Aldrich), while bacterial isolates were cultured in Luria-Bertani (LB) broth (Merck) at 37 °C 
in a rotary shaker (SciQuip) for 24 hours. Following incubation, cultures were placed on ice and processed for 
DNA isolation immediately. The identity of all fungal isolates was confirmed by sequencing of their ribosomal 
DNA region and BLAST analysis (http://blast.ncbi.nlm.nih.gov).
nucleic acids extraction. One millilitre aliquots of yeast and bacterial cultures were transferred to 1.5 ml 
microcentrifuge tubes and centrifuged at 16,000 × g in a bench microcentrifuge for 2 minutes to pellet the cells. 
The supernatant was discarded and the bacterial and yeast cell pellets were processed as follows. The bacterial 
cell pellet was resuspended in 60 µl of 10 mg/ml lysozyme and incubated at 37 °C for 30 minutes to ensure effi-
cient cells lysis. The yeast cell pellet was resuspended in 300 µl of lysis buffer from the Wizard Genomic DNA 
Purification kit (Promega). Following addition of 200 mg of 500-micron glass beads (BioSpec Products) yeast cells 
were homogenised with a FastPrep-24 instrument (MP Biomedicals) using five pulses with 60 seconds cooling 
intervals at 6.5 m/s speed setting. Cell debris was removed by centrifugation at 16,000 × g for 2 minutes, and the 
supernatant was transferred to fresh tubes for DNA isolation following the manufacturer instructions. Briefly, 
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Figure 8. MPA technology principles: probes and melting curves. (a) Probes consist of a target-hybridising 
oligonucleotide (THO) labelled with a fluorophore (F) at the 5′end and quencher (Q) at the 3′end; the THO is 
shown hybridised to a partially complementary oligonucleotide (PCO). Mismatches are represented by red dotted 
lines. (b) In aqueous solution and low temperature the annealed THO: PCO pair is fluorescent due to the relatively 
high atomic distance between the fluorophore and the quencher. Exposure to increased temperature leads to 
thermal dissociation of the hybrid reaching a maximum rate at the corresponding dissociation temperature (Tm). 
As the THO becomes detached, it assumes a randomly coiled conformation causing a drop in atomic distance 
between fluorophore and quencher and a corresponding decrease in fluorescence. Thus the melting curve shows 
decreased fluorescence emission with increasing temperature. (c) The negative derivative plot of the emission 
reading versus temperature reveals a positive value of the melting peak at the corresponding Tm.
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cellular proteins were removed by a salt precipitation step and the DNA was concentrated and desalted by iso-
propanol precipitation. The DNA was resuspended in 50 µl of DNA Rehydration Solution, a process optimised by 
incubating at 65 °C for 1 hour.
Cloned plasmid DNA was purified from bacterial cells using a QIAprep Miniprep Kit (Qiagen) according 
to the manufacturer instructions. Briefly, samples were subjected to alkaline lysis in buffer PB and neutralised. 
Cleared lysates were applied to QIAprep purification columns under high-salt concentration affinity binding con-
ditions and eluted in 30 µl of elution buffer. In all cases, the concentration of purified DNA was measured using a 
NanoDrop 1000 spectrophotometer (Thermo Scientific) and stored at 4 °C until use.
primer and hydrolysis probe design. Fungal ribosomal DNA (rDNA) sequences were retrieved from 
GenBank and the International Society for Human and Animal Mycoses (ISHAM) ITS database and aligned 
using CLUSTALW2 or CLUSTAL Omega (EMBL-EBI; https://www.ebi.ac.uk/Tools/msa/clustalo). Sequences 
were manipulated and analysed using the BioEdit Sequence Alignment Editor Version 7.2.3. Primers and probes 
were designed within the rDNA region. Primers used in the MPA-Candida assay were the universal forward 
primer, LR0 and specifically designed reverse primer, GSCand. A universal pan-fungal primer set ITS3 and LR1 
was selected to amplify the region containing the pan-fungal probe. The dual-labelled Candida probes were 
designed to specifically target the D1/D2 of the LSU rDNA region from at least 15 different Candida species. 
The pan-fungal probe was designed based on the internal transcribed spacer (ITS) sequences. MPA probes 
were designed using the nucleic acid folding and hybridisation prediction software UNAFold (http://unafold.
rna.albany.edu). All primers and probes were subjected to reverse BLAST in GenBank (http://blast.ncbi.nlm.
nih.gov) to test for cross-homology with other microorganisms. Universal bacterial 16S forward primer 516F: 
5′-TGCCAGCAGCCGCGGTAA-3′ and reverse primer 806R: 5′-GGACTACCAGGGTATCTAAT-3′42 set was 
used for positive control in cross-reactivity experiments. MPA-Candida and pan-Fungal reaction sets are shown 
in Table 4.
MpA-Candida and pan-fungal real-time qpcR assay. The amplification assay was carried out 
in a LightCycler 480 Instrument II Real-time PCR unit (Roche Diagnostics) using a 384-well plate format. 
Amplification reactions were performed in 20 µl final volume reactions containing 2× LightCycler 480 Probes 
Master (Roche Diagnostics), 0.6 µM each primer, optimised concentrations of 0.2 µM pan-Candida THO, 0.4 µM 
C. krusei-specific THO, 0.4 µM C. glabrata-specific THO, 0.4 µM C. auris-specific THO and 0.4 µM internal 
control THO. Each THO was combined with the corresponding PCO at a ratio of 1:2. As for the pan-Fungal 
assay, both the pan-fungal and internal control probes were present at a concentration of 0.4 µM. Template DNA 
included 1 µl of internal control plasmid DNA (106 copies) and 1 µl of either cloned (plasmid) or genomic fungal 
DNA (1 to 105 copies/GEs) per reaction. Real-time PCR conditions were as follows: an initial step of 9 min 30 sec 
at 95 °C, followed by 50 cycles at 95 °C for 20 sec, 62 °C for 30 sec, and 72 °C for 1 min and temperature maintained 
at 95 °C for 10 sec before melting curve profiling increases from 20 °C to 80 °C. Two detection channels, FAM (465 
nm/510 nm) and HEX (533 nm/580 nm) were activated for fluorescence measurements during the read steps at 
72 °C for each experiment. The specificity of the pan-fungal probe was evaluated from the amplification curve 
whereas those of Candida MPA probes were evaluated from their melt curve profiles. The amplification curve 
threshold cycle (Ct) of the pan-Fungal reaction was standardised by an automatic threshold setting whereas for 
MPA-Candida reaction the threshold line was set at 5 in Fit Points analysis method using the LightCycler 480 
software version 1.5 (Roche Diagnostics). Both, the MPA and pan-Fungal reactions contain an internal control 
to ascertain assay functionality. The internal control probe consists of a unique nucleotide sequence cloned into 
the pCR 2.1-TOPO vector that has no identity to any entry in the non-redundant nucleotide databases at NCBI. 
To further demonstrate assay specificity, each probe was evaluated for detection of either genomic fungal DNA or 
plasmid DNA carrying the corresponding target sequence. In order to prepare cloned plasmid DNAs, first-round 
PCR amplicons of the C. albicans, C. dubliniensis, C. parapsilosis, C. tropicalis, C. glabrata, C. guilliermondii, C. 
auris and C. krusei were cloned into the pCR 2.1-TOPO vector using the TOPO TA Cloning system (Invitrogen). 
The resulting plasmid with insert was quantified and sequenced to confirm amplicon identity.
MpA-Candida melting curve qualitative analysis. MPA-Candida assay relies on a novel melting curve 
analysis for multiple targets in one reaction. Dual-channel melting curves were obtained by measuring the fluo-
rescence of the labelled THOs at different temperatures (from 20 to 80 °C). The fluorescence emission data was 
Reaction Type Probe target Detection channel Primer set
MPA
C. krusei
FAM
Forward: LR043 & Reverse: GSCand (this study)
Pan-Candida
C. glabrata
C. auris
HEX
Internal Control Forward: M13 (−20) & Reverse: M13 (−29)
qPCR
Pan-Fungal FAM Forwards: ITS344 & Reverse: LR145
Internal Control HEX Forward: M13 (−20) & Reverse: M13 (−29)
Table 4. Description of the MPA-Candida and pan Fungal assays. FAM: 6-carboxy-fluorescein; 465 nm/510 
nm; HEX: Hexachloro-fluorescein; 538 nm/580 nm. For simplicity and flexibility, the MPA-Candida assay was 
engineered as a two-tube system, run simultaneously under the same experimental conditions.
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continuously collected at five acquisitions per degree Celsius and analysed by using the Tm Calling algorithm 
of the LightCycler 480 Software version 1.5 (Roche Diagnostics). Melting curves were displayed as fluorescence 
against temperature charts and plotted by representing the negative fluorescence derivative melting curve against 
temperature (−dF/dT). The point of inflection represents the melting point of the hybrid THO:PCO in the no 
DNA control reaction. In the presence of the target sequence, the corresponding probe will be hydrolysed during 
amplification, which will result in the appearance of a reduced peak in the post-amplification melt curve analysis. 
The no DNA control melt curve was used for comparison.
Standard curve. Standard curve functions to assess unknown target copy number were developed using 
the pan-Fungal qPCR assay. Recombinant plasmid DNAs of C. albicans, C. dubliniensis, C. krusei, C. glabrata, C. 
auris, C. parapsilosis, C. tropicalis, C. guilliermondii were serially diluted for detection from 106 to 102 copies per 
reaction. Regression lines were obtained by plotting the logarithm of the initial plasmid copy number versus the 
corresponding Ct and used to determine the sensitivity and efficiency of the assay. Amplification efficiency (E) 
was calculated by E = 10-1/b− 1, where b is the slope of the linear regression equation.
pcR assay reproducibility. Intra- and inter-assay reproducibility was assessed by two independent exper-
iments of eight Candida species plasmid DNAs. The coefficient of variation (CV) calculated for Ct data was used 
as an indicator of relative precision and reproducibility. CV was determined by dividing the standard deviation 
(SD) by the arithmetic mean of the measured values: CV (%) = (SD/mean value) × 100.
Data Availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information Files). Materials are available from the corresponding author on reasonable request.
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